Genomic profiles of low-grade murine gliomas evolve during progression to glioblastoma

• Published in: Neuro-oncology (Charlottesville, Va.) Vol. 19; no. 9; pp. 1237 - 1247
• Main Authors: Vitucci, Mark, Irvin, David M, McNeill, Robert S, Schmid, Ralf S, Simon, Jeremy M, Dhruv, Harshil D, Siegel, Marni B, Werneke, Andrea M, Bash, Ryan E, Kim, Seungchan, Berens, Michael E, Miller, C Ryan
• Format: Journal Article
• Language: English
• Published: England Oxford University Press 01.09.2017
• Subjects: Animals; Basic and Translational Investigations; Brain Neoplasms - genetics; Brain Neoplasms - pathology; Cell Transformation, Neoplastic - genetics; Disease Progression; Genomics - methods; Glioblastoma - genetics; Glioblastoma - pathology; Glioma - genetics; Glioma - pathology; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Mutation; genetically engineered mouse; glioma; progression; glioblastoma; transcriptome
• ISSN: 1522-8517; 1523-5866
• DOI: 10.1093/neuonc/nox050

Gliomas are diverse neoplasms with multiple molecular subtypes. How tumor-initiating mutations relate to molecular subtypes as these tumors evolve during malignant progression remains unclear. We used genetically engineered mouse models, histopathology, genetic lineage tracing, expression profiling, and copy number analyses to examine how genomic tumor diversity evolves during the course of malignant progression from low- to high-grade disease. Knockout of all 3 retinoblastoma (Rb) family proteins was required to initiate low-grade tumors in adult mouse astrocytes. Mutations activating mitogen-activated protein kinase signaling, specifically KrasG12D, potentiated Rb-mediated tumorigenesis. Low-grade tumors showed mutant Kras-specific transcriptome profiles but lacked copy number mutations. These tumors stochastically progressed to high-grade, in part through acquisition of copy number mutations. High-grade tumor transcriptomes were heterogeneous and consisted of 3 subtypes that mimicked human mesenchymal, proneural, and neural glioblastomas. Subtypes were confirmed in validation sets of high-grade mouse tumors initiated by different driver mutations as well as human patient-derived xenograft models and glioblastoma tumors. These results suggest that oncogenic driver mutations influence the genomic profiles of low-grade tumors and that these, as well as progression-acquired mutations, contribute strongly to the genomic heterogeneity across high-grade tumors.